Skip to main content

Table 1 Efficacy data summary (from the RATIFY clinical trial cut-off)

From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom

  MIDO-treated patients SOC-treated patients
Overall survival (non-censored), % 46 42
Event-free survival, % 27 18
Stem cell therapy received during trial, % 59 55
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us